2025-11-11T19:05:25-06:00 2024-12-31 320577874 Allworth Tax Solutions 340 Palladio Parkway Ste 501 Folsom CA 95630 990 2024-01-01 943473864 Lifespan Research Institution LIFE 6503361780 110 Pioneer Way J Mountain View CA 94041 Keith Comito CEO 6503361780 2025-11-11 1 1 Allworth Tax Solutions P01730806 9256852911 2025-11-11 2024 2025-03-06 01:10:19Z Keith Comito 110 Pioneer Way J Mountain View CA 94041 1819303 0 X www.lifespan.io X 2009 CA Develop, promote and ensure widespread access to rejuvenation biotechnologies. 7 7 48 9 442 0 348261 419258 0 75945 429858 299964 36441 1003955 814560 1799122 1573325 182691 0 0 3728192 3775227 0 0 737548 2231697 2562600 7533214 6520518 -6718654 -4721396 15127697 9626341 2175768 913563 12951929 8712778 X Lifespan Research Institute ("LRI") is a 501(c)(3) nonprofit organization focused on the defeat of age-related disease and the extension of healthy human lifespan through raising funds and awareness for scientific work addressing the root causes of the aging process, building a thriving ecosystem of mission aligned stakeholders which can be mobilized to strategic action, and spearheading relevant research projects directly. We work to identify, develop, and promote initiatives with outsized impact and the greatest potential to realize widespread access to regenerative medicine solutions targeting the disabilities and diseases of aging. 0 0 3105866 109824 The research program is carried out both in the Organization's Mountain View facility by employees of the Organization and at some of the most prestigious institutions around the world. The program is comprised of both internal and external research programs. There are currently two (2) separate lines of internal research: Mitochondrial mutations and Immuno-senescence. The Mitochondrial mutations line of research has published work and contains four (4) subprojects, some of which involve collaborations with outside institutions. The Immuno-senescence line of research has also published work and contains nine (9) subprojects, also involving collaborations with outside institutions. There are currently two (2) external research projects ongoing at outside institutions. Funding for these programs continue to be prioritized for projects that meet our company mission and are currently being unaddressed in our intramural research program. 868809 72867 12000 Education - As part of its mission, the Organization is committed to educating students and the public about rejuvenation biotechnologies. The Organization's student program, Education, is committed to educating students and the public. Education operates a summer internship program that places twelve (12) undergraduate students at the Research Center and outside institutions. It also continues a program to place nine (9) post-baccalaureate students at various institutions, including four (4) at the SRF Research Center. 2022 saw the expansion of SRF's Master's program in conjunction with Dominican University of California and the formation of a new graduate internship program to host graduate students from other institutions. SRF now has had one (1) Master's student graduate from the Master's program in 2023, has successfully hosted two (2) graduate interns in the past, and is currently hosting one (1) new graduate intern who joined in 2024. 498310 60805 Marketing/Media - In addition to participation in a variety of scientific and public engagements, the Organization organizes its own virtual marketing campaigns, conferences, and events. This outreach is intended to inform both the scientific community and the public about the field of rejuvenation biotechnology. The Organization paused conferences in 2024 and 2025 due to the merger but plans to resume in-person conferences in 2026. 119819 6931 Longevity Investor Network As part of the Organization's mission to build an ecosystem of aligned stakeholders, LRI's investor network catalyzes private investment in biotechnology companies developing interventions that target the root mechanisms of aging. In 2024, the Organization hosted a successful Longevity Investor Network event in San Francisco, bringing together start-ups and investors within the rejuvenation biotechnology field. In addition, the LIN hosts weekly virtual pitch sessions at which start-ups present their companies to a group of investors. Lifespan News As part of the Organization's mission to inform the public about the latest news in the longevity biotech field, LRI hosts its own news outlet with weekly articles about the latest publications and breakthroughs in the field. Other programs - The Organization conducts other programs related to the mission of the organization. 119819 6931 4592804 1 1 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 0 0 0 0 1 0 0 0 0 0 1 1 1 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 1 20 0 1 48 1 0 0 0 0 0 0 0 0 0 0 0 0 X 7 7 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X The Organization 6503361780 110 Pioneer Way J Mountain View CA 94041 Keith Comito Started 10124 President 40.00 X X 0 0 0 Oliver Medvedik Started 10124 Secretary 40.00 X X 0 0 0 Paul Spiegel Started 10124 Chairman of the Board 1.00 X X 0 0 0 Andrew Aiello Started 10124 Treasurer 5.00 X X 0 0 0 Kevin Dewalt Board Member 1.00 X 0 0 0 Barbara Logan Board Member 1.00 X 0 0 0 Kevin Perrott Terminated 122724 Treasurer and Secretary 5.00 X 0 0 0 Bill Lao Chairman of the Board 5.00 X X 0 0 0 Lisa Fabiny-Kiser Chief Executive Officer 40.00 X 230054 0 62373 Stephanie Dainow Chief Business Officer 40.00 X 179056 0 9508 Maria Entraigues Abramson Director of Development 40.00 X 146296 0 26812 Emily Lillian Fishman Director of Education 40.00 X 145710 0 21124 Miguel Moreno-Garcia Terminated 102 Director of Research 40.00 X 145702 0 33871 Kelly Boemmel Director of Operations 40.00 X 144900 0 19268 991718 0 172956 9 0 1 0 Goodwin Proctor LLP 100 Northern Ave Boston MA 02210 Legal Services 110447 1 X 419258 77136 419258 Report services 541900 60000 60000 Conference registrations 611600 12000 12000 LIN services income 541900 3945 3945 75945 297569 297569 22576 20181 2395 2395 2500 -105 Gain on extinguishment of grants 900099 1000000 1000000 Miscellaneous income 900099 2222 2222 Miscellaneous gain - programs 900099 1291 1291 442 442 1003955 1799122 79736 442 1299686 22595 22595 50272 50272 109824 109824 240000 84000 60000 96000 2791556 2095737 281893 413926 69856 51278 11435 7143 442839 311030 55411 76398 230976 166247 26020 38709 291199 291199 95686 95686 510082 364375 131479 14228 5943 5943 11479 403 11076 751727 690955 50413 10359 47798 1203 43011 3584 134605 55213 7334 72058 304550 271495 33055 19337 19337 Equipment and supplies 231935 231935 Small computer equipmen 67199 23439 42302 1458 Patentry fees 36110 36110 Immigration fees 12545 12545 42405 8205 30515 3685 6520518 4592804 1190166 737548 12209933 6184099 133 60148 13948 2671132 1398234 1568279 1272898 44176 65757 36142 504866 158500 963886 1096586 574687 15127697 9626341 213928 442828 1000000 961840 470735 2175768 913563 X 12502865 8557635 449064 155143 12951929 8712778 15127697 9626341 X -4721396 130548 23134 328563 X X 1 X 0 1 0 X 3869523 29951591 1205845 348262 419259 35794480 3869523 29951591 1205845 348262 419259 35794480 3115402 32679078 21397 152012 46782 428747 297569 946507 36740987 333913 0.88940 0.87310 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2327125 1090799 1236326 344007 307435 36572 1272898 Crypto currency 504866 F 504866 Program related investment 963886 F 963886 Prepaid expenses 56987 Deposits 25321 Unamortized Tenant Improvement Allowance (Net) 53780 Right of Use Assets 438599 574687 Lease Liability 470735 470735 X Part X, Line 2: The Organization evaluates its uncertain tax positions and will recognize a loss contingency when it is probable that a liability has been incurred as of the date of the financial statements and the amount of the loss can be reasonably estimated. The amount recognized is subject to estimate and management judgment with respect to the likely outcome of each uncertain tax position. The amount that is ultimately sustained for an individual uncertain tax position or for all uncertain tax positions in the aggregate could differ from the amount recognized. As of December 31, 2024, management did not identify any uncertain tax positions. 1 0 0 0 0 0 0 0 0 0 Arthur-Scheunert-Allee 114-116 Nuthetal 14558 Germany Funding for external research project 15250 Wire 0 Margaret Telfer Bldg Cashiers Level 4 7-79 Arundel Street Funding for external research project 94574 Wire 0 2 0 0 0 0 0 0 1 Sanford-Burnham Medical Research Inst 10901 N Torrey Pines Rd La Jolla CA 92037 510197108 501c3 12000 0 Funding for Educational student The Regents of the University of California Berkeley 1608 Fourth Street Suite 201 Berkeley CA 94710 946002123 501c6 10595 0 Funding for Educational student 2 Research grants 5 50272 Part I, Line 2: The Organization monitors grants at three month intervals. We require interim research reports every three months, which are submitted with the next payment invoice. At the conclusion of each research contract, we require a comprehensive research report and a financial accounting that details how the grant was spent. X X 0 0 0 0 0 0 0 0 0 Lisa Fabiny-Kiser Chief Executive Officer 230054 0 0 0 0 0 9600 0 52773 0 292427 0 0 0 Stephanie Dainow Chief Business Officer 179056 0 0 0 0 0 0 0 9508 0 188564 0 0 0 Miguel Moreno-Garcia Terminated 102 Director of Research 145702 0 0 0 0 0 0 0 33871 0 179573 0 0 0 Maria Entraigues Abramson Director of Development 146296 0 0 0 0 0 0 0 26812 0 173108 0 0 0 Emily Lillian Fishman Director of Education 145710 0 0 0 0 0 5984 0 15140 0 166834 0 0 0 Kelly Boemmel Director of Operations 144900 0 0 0 0 0 5916 0 13352 0 164168 0 0 0 PrimeWarp Studios LLC Entity owned by Treasurer, Andrew Aiello 22500 YouTube channel owned by organization was sold to PrimeWarp Studios 0 X 29 5057 FMV X HET3 Mice 110 47410 FMV 0 0 0 Part I, Column (b): Number of units contributed Form 990, Part VI, Section B, line 11b The form 990 is reviewed by the Executive Director and presented to the Board prior to filing. Form 990, Part VI, Section B, line 12c A formal conflict of interest policy has been adopted by the organization. The policy is reviewed and reaffirmed annually. Form 990, Part VI, Section B, line 15 The officer salaries are determined through the budget process by the board of directors. The board used comparable data for determining salaries of all key employees. Form 990, Part VI, Section C, line 18 The forms 1023 and 990 are available at the organization's offices upon request. Form 990, Part VI, Section C, line 19 All governing documents, the conflict of interest policy and the financial statements are available at the organization's offices upon request Form 990 Part VI Additional Organizational Information Part VI Additional Organizational Information Organizational Merger and Continuity of Exemption Effective October 4, 2024, SENS Foundation, Inc. (EIN 94-3473864), a California nonprofit public benefit corporation recognized as tax-exempt under IRC 501(c)(3), completed a statutory merger with Lifespan Extension Advocacy Foundation Inc. (EIN 46-5328762), a New York not-for-profit corporation. The merger was approved by the boards of directors of both organizations pursuant to an Agreement and Plan of Merger executed in 2024. Upon completion of the merger, SENS Foundation, Inc. became the surviving corporation and changed its legal name to Lifespan Research Institution. The Internal Revenue Service has acknowledged this name change. The surviving organization continues to be recognized as exempt under IRC 501(c)(3) and classified as a public charity under 509(a)(1) and 170(b)(1)(A)(vi). A Certificate of Merger was filed with the California Secretary of State on October 4, 2024 (Certificate No. XXX-XX-XXXX), following non-objection clearance from the California Attorney General's Charitable Trusts Section dated April 22, 2024, in compliance with California Corporations Code 6010(b). The New York Attorney General's Charities Bureau was also notified consistent with New York Not-for-Profit Corporation Law. All assets, liabilities, and donor-restricted funds of Lifespan Extension Advocacy Foundation Inc. were transferred by operation of law to the surviving California organization. No assets were distributed to private individuals or non-charitable entities. All donor-restricted assets remain dedicated to their original exempt purposes. The surviving organization continues to conduct the charitable, scientific, and educational programs of both predecessor entities, including research, public education, and advocacy in regenerative medicine and longevity science. There have been no material changes in exempt purpose, mission, or operations. Lifespan Extension Advocacy Foundation Inc. (EIN 46-5328762) has filed or will file a final Form 990 marked "Final Return / Terminated and include Schedule N, Part I reporting the transfer of all assets to Lifespan Research Institution (EIN 94-3473864). This merger consolidated overlapping operations and governance under a single California-based 501(c)(3) entity to enhance program efficiency and strengthen the mission of advancing longevity science and regenerative research. Form 990 Part VIII Line 11 Other Revenue Extinguishment of Debt: During the year, the organization reversed a grant payable previously accrued and reported in a prior Form 990 because the grantee did not satisfy required reporting conditions. The Organization recognized the extinguishment as Other Revenue on Line 11a, Part VIII. Form 990, Part XI, line 9: Net assets attributable to LEAF 328,563. Form 990, Part XII, Line 2b/c The Organization's audit committee is charged with the responsibility of overseeing the audit and review work of the independent CPAs. This process has not changed from prior years. Form 990 Part XI, Line 8 Prior Period Adjustments In December 2023, the Financial Accounting Standards Board issued ASU 2023-08, Intangibles Goodwill and Other (Crypto Assets), requiring eligible crypto assets to be measured at fair value. The Organization elected early adoption of this standard for the year ended December 31, 2024, resulting in a $23,134 increase in beginning net assets to reflect fair value as of the adoption date.